Keywords: evotec, initiates, ph, study, p2x7, blocker, german

Evotec initiates Ph I study of P2X7 blocker

Article | 20 October 2008

Print This

German drug developer Evotec AG has initiated Phase I clinical studies of its proprietary, small-molecule P2X7 receptor antagonist.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in